Название документа

Ko-Amlessa's tablets are shown for treatment of arterial hypertension at patients who need treatment perindoprily, indapamidy and amlodipiny in a dose, available in the fixed combination.

Structure

Active ingredients: a perindoprila it is grated - butylamine, indapamid, amlodipin;

1 tablet contains

:

by

2 mg of a perindopril it is grated - to butylamine, 0.625 mg of an indapamid and 5 mg of an amlodipin (in the form of an amlodipin besilat), or

by

4 mg of a perindopril it is grated - to butylamine, 1.25 mg of an indapamid and 5 mg of an amlodipin (in the form of an amlodipin besilat), or

by

4 mg of a perindopril it is grated - to butylamine, 1.25 mg of an indapamid and 10 mg of an amlodipin (in the form of an amlodipin besilat), or

by

8 mg of a perindopril it is grated - to butylamine, 2.5 mg of an indapamid and 5 mg of an amlodipin (in the form of an amlodipin besilat), or

by

8 mg of a perindopril it is grated - to butylamine, 2.5 mg of an indapamid and 10 mg of an amlodipin (in the form of an amlodipin besilat).

Excipients: cellulose microcrystalline Calcii chloridum, hexahydrate; corn starch; starch sodium (type A) Natrii hydrocarbonas; silicon dioxide water; magnesium stearate.

Contraindication

  • Hypersensitivity to a perindopril or to the APF any other inhibitor to an indapamid or to any other streptocides, to an amlodipin or dihydropyridine and to any of excipients.
  • Quincke's disease (Quincke's edema) in the anamnesis connected with the previous treatment by APF inhibitors.
  • Congenital or idiopathic Quincke's disease.
  • Hepatic encephalopathy.
  • Heavy abnormal liver function.
  • Hypopotassemia.
  • Heavy arterial hypotension.
  • Shock, including cardiogenic shock.
  • Obstruction of an exit from a left ventricle (for example a stenosis of an aorta of heavy degree).
  • Heart failure with an unstable hemodynamics after an acute myocardial infarction.
  • Not treated dekompensirovanny heart failure.
  • Co-administration with the medicaments containing active ingredient aliskiren, to patients with diabetes or a renal failure (glomerular filtration rate <60 ml/min. / 1.73 sq.m).
  • Use to the patients who are on a hemodialysis.
  • Renal failure of heavy degree (the clearance of creatinine is lower than 30 ml/min.).
  • Renal failure of average degree (the clearance of creatinine is lower than 60 ml/min.) at administration of medicament of Ko-Amlessa, containing a combination of active ingredients in doses of 8 mg / 2.5 mg / 5 mg or 8 mg / 2.5 mg / 10 mg.
  • Pregnancy or period of planning of pregnancy.
  • feeding Period breast.
  • Children's age.
for

Route of administration

to

1 tablet of medicament of Ko-Amlessa a day once, it is desirable in the morning before food.

Use of the fixed combination is not provided by

for initial therapy.

In case of need a dose of medicament of Ko-Amlessa can be changed

or individual selection of doses separately on each component can be recommended.

In case of need the patient can divide the tablet Co-Amlessa on 4 mg / 1.25 mg / 10 mg or on 8 mg / 2.5 mg / 10 mg at the level of a dose, having put it on a plain surface line up and having pressed two fingers on both sides from risks.

Maximum recommended Co-Amless's dose - 8 mg / 2.5 mg / 10 mg a day.

to

Feature of use

to

Pregnant

to

It is contraindicated.

by

Children

it is not applied.

Drivers

With care.

Overdose

Data on overdose by Ko-Amlessa's medicament are absent.

For a combination perindopril/indapamid frequent undesirable reaction at overdose is arterial hypotension which can sometimes be followed by nausea, vomiting, spasms, dizziness, drowsiness, confusion of consciousness, an oliguria which can progress to an anury (owing to a hypovolemia). There can be disturbances of water and electrolytic balance (decrease in level of potassium and sodium in blood plasma).

Measure of first aid include fast removal of medicament from an organism: gastric lavage and/or prescribing of activated carbon, and then recovery of water and electrolytic balance in the conditions of a hospital until these indicators return to norm limits.

in case of developing of considerable hypotension should give to the patient horizontal position with a low headboard. If necessary enter isotonic solution intravenously or use any other method of restoration of volume of blood.

Perindoprilat, the active form perindoprit, it is possible to remove from an organism by means of a hemodialysis.

Side effects

Most frequent side reactions which were observed at use of a perindopril, an indapamida and an amlodipina separately are: dizziness, a headache, paresthesias, vertigo, drowsiness, a disorder of vision, a ring in ears, palpitation, inflows, arterial hypotension (and the related symptoms), cough, short wind, disturbances from digestive tract (abdominal pain, a constipation, diarrhea, a food faddism (dysgeusia), dyspepsia, nausea, vomiting), an itching, skin rashes, makulopapulezny rashes, myotonia, an asthenia, hypostasis of anklebones, hypostasis and fatigue.

Interaction

Aliskiren. At the patients sick with diabetes, or patients with impaired renal function the risk of emergence of a hyperpotassemia, deterioration in function of kidneys and cardiovascular incidence and mortality increases.

Medicines which cause a hyperpotassemia. Some medicines or therapeutic classes of medicines can cause a hyperpotassemia, namely: aliskiren, potassium salts, kaliysberegayushchy diuretics, APF inhibitors, antagonists of receptors of angiotensin II, non-steroidal anti-inflammatory medicaments (NPVS), heparin, immunosuppressors, such as cyclosporine or takrolimus, Trimethoprimum. The concomitant use of the specified medicines increases risk of emergence of a hyperpotassemia.

Storage conditions

to Store

at a temperature not above 30 °C in original packing for protection against effect of light and moisture.

to Store

out of children's reach.

Expiration date - 2 years.

Characteristics
Active ingredients Amlodipin, Indapamid, Perindopril
Amount of active ingredient 8 mg + 2.5 mg + 10 mg
Applicant KRK
Code of automatic telephone exchange C09BX01 Perindopril, amlodipin and indapamid
Interaction with food To
Light sensitivity Sensitive
Market status The branded generic
Origin Chemical
Prescription status According to the prescription
Primary packing blister
Producer KRK D.D.
Quantity in packing 30 tablets (3 blisters on 10 pieces)
Release form tablets for internal use
Route of administration Oral
Sign Import
Storage temperature from 5 °C to 30 °C
Trade name Ko-Amlessa

Reviews Ko-Amlessa of the tab. 8mg/2.5mg/10mg No. 30

5 Rating 1 Reviews

Quality
Speed
Delivery
Performance
Price

Ko-Amlessa of the tab. 8mg/2.5mg/10mg No. 30

  • Product Code: 182161
  • In Stock

  • Ready to ship
  • $29.18


Related Products

Last Viewed

Модули для Opencart